Bortezomib Injection

Get a Price/Quote

Bortezomib Injection Specification

Indication
Multiple Myeloma, Mantle Cell Lymphoma

Salt Composition
Bortezomib 2 mg/vial

Dosage Form
Lyophilized Powder for Injection

Enzyme Types
Proteasome Inhibitor (not an enzyme but acts on enzyme pathways)

Feature
Sterile, Single-use Vial

Ingredients
Bortezomib, Mannitol (as excipient)

Application
Anticancer Therapy

Ph Level
pH 4.0-5.0 after reconstitution

Physical Color/Texture
White to Off-white Lyophilized Powder

Fermentation Smell
Odorless

Enzymatic Activity
Inhibits 26S Proteasome activity

Storage Instructions
Store at 2C to 8C (Refrigerated)

Shelf Life
2 years

Bortezomib Injection Trade Information

FOB Port
All Indian Port

Payment Terms
Western Union, Paypal, Telegraphic Transfer (T/T), Cash in Advance (CID)

Delivery Time
7 Days

Sample Available
Yes

Sample Policy
Sample costs shipping and taxes has to be paid by the buyer

Packaging Details
As Per Standard Packing

Main Export Market(s)
Australia, South America, Eastern Europe, Western Europe, Middle East, Africa, Central America, Asia, North America

Certifications
ISO, GMP, WHO

About Bortezomib Injection

Product Name : Bortezomib Injection
Trade Name : Bortecad, Bortenat
Available Strength : 2mg, 3.5mg
Packing : Sterile Single Dose vial (Lyophilized)
Pack Insert/Leaflet : Yes
Therapeutic use : Anti Cancer
Production Capacity : 10,000 inj./Month

What Is Bortezomib?
Bortezomib contains the active substance bortezomib, the so-called proteasome inhibitor which plays important role in controlling the growth and function of the cell.

Bortezomib Injection Uses
This medication is used for the treatment of

Multiple Myeloma
Mantle Cell Lymphoma

How Does Bortezomib Injection Works?
It works by helping the breakdown down proteins that the cell doesnt need and blocks the proteasomes so the protein builds up inside the cell which causes cell death.

Available Strength:

Bortezomib 2Mg
Bortezomib 3.5Mg

Advanced Anticancer Solution

Bortezomib Injection offers a potent therapeutic option for individuals diagnosed with multiple myeloma and mantle cell lymphoma. By inhibiting 26S proteasome activity, it disrupts cellular pathways critical for cancer cell survival. With a shelf life of two years and compliance to international standards, this product represents a reliable choice for oncology practices worldwide.

Efficient Prescribing, Safe Handling

This prescription-only medicine is handled exclusively by healthcare professionals due to its cytotoxic nature. Enclosed in a sterile, single-use vial, batch and expiry information are visibly printed to support quality assurance. Strict storage protocols ensure medication stability, preserving efficacy for patient treatment programs.

FAQs of Bortezomib Injection:

Q: How is Bortezomib Injection administered to patients?

A: Bortezomib Injection must be reconstituted with 0.9% sodium chloride injection and administered either intravenously (IV) or subcutaneously (SC) by trained healthcare professionals. Self-administration is not permitted due to its cytotoxic properties.

Q: What conditions is Bortezomib Injection used to treat?

A: This medication is indicated for the treatment of multiple myeloma and mantle cell lymphoma, offering targeted action against malignant cells as part of anticancer therapy.

Q: When should Bortezomib Injection not be used?

A: Bortezomib Injection is contraindicated in individuals with hypersensitivity to bortezomib, boron-containing compounds, or any formulation ingredients. It should not be given outside prescribed contexts.

Q: Where should Bortezomib Injection be stored for optimal efficacy?

A: The injection must be stored refrigerated at 2C to 8C, away from direct light and temperature fluctuations to preserve potency and safety.

Q: What is the process for preparing Bortezomib Injection before use?

A: To prepare the injection, the lyophilized powder is reconstituted with 0.9% sodium chloride solution. The resulting solution should have a pH of 4.05.0 and must be visually inspected for particulate matter prior to administration.

Q: What benefits does Bortezomib Injection provide in cancer therapy?

A: By inhibiting the 26S proteasome pathway, bortezomib disrupts processes essential for cancer cell growth and survival, improving outcomes for patients with certain hematologic malignancies.

Q: Who can prescribe and handle Bortezomib Injection?

A: Only licensed healthcare professionals are authorized to prescribe, reconstitute, and administer Bortezomib Injection due to its cytotoxic effects and prescription-only status.

Tell us about your requirement